Intended Audience
Figure 1: Bone Metastasis Market Share, by Region
Sources: WHO, Oncology Reviews, American Society of Clinical Oncology, Cancer Research U.K., Journal of Spine Surgery, Annual Reports, Press Release, White Paper, and Company Presentation
The bone metastasis market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the bone metastasis market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others.
On the basis of diagnosis, the bone metastasis market is categorized into biopsy, blood test, imaging, and others. The imaging segment is sub-segmented into X-ray, bone scintigraphy, computerized tomography, magnetic resonance imaging, positron emission tomography, and others.
On the basis of the treatment, the bone metastasis market is segmented into medical therapies, surgery, medication, and others. The medical therapies segment is sub-segmented into chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others. The ablation therapy segment is further segmented into radiofrequency ablation, cryoablation, and others. The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and others. The medication segment is sub-segmented into pain medications, bone building medications, and others. The pain medication segment is sub-segmented into ibuprofen, morphine, and others. The bone-building medications segment is sub-segmented into corticosteroids, bisphosphonates, and others. The bisphosphonates segment is further segmented into teriparatide, pamidronate, medronate, and others.
On the basis of end-user, the bone metastasis market is segmented into hospitals and clinics, diagnostic centers, pharmacies, and ambulatory surgical centers.
America dominates the bone metastasis market. This can be attributed to the presence of a well-developed healthcare sector, the increasing prevalence of breast cancer, and increasing healthcare sector within the region. Moreover, the presence of key players such as Merck & Co., Inc. and Pfizer Inc. within the Americas boosts the regional market growth.
Europe is the second in the bone metastasis market owing to the availability of funds for research and a huge patient population. According to the Cancer Research U.K., approximately 55,122 new cases of invasive breast cancer were reported in 2015. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe leads the regional market due to the presence of developed economies within the region.
Asia Pacific is projected to be the fastest growing region in the bone metastasis market. The presence of developing economies such as India and China, a developing healthcare sector, and the growing prevalence of cancer within the region drive the market growth in the region. Moreover, favorable government policies and increasing penetration of key market players within the region fuel the market growth.
The Middle East and Africa holds the least share in the bone metastasis market, owing to the presence of poor economies, stringent government policies, and lack of healthcare services, especially within the African region. A majority of the market of bone metastasis in the Middle East and Africa is held by the Middle East due to the presence of a well-developed healthcare sector and huge healthcare expenditure by developed economies such as Saudi Arabia, Kuwait, Dubai, and others within the region.
Recent Development
The key players in the bone metastasis market are:
| Report Attribute/Metric | Details |
| Market Size | USD 17.5 Billion by 2032 |
| CAGR | 9.4% |
| Base Year | 2022 |
| Forecast Period | 2023-2032 |
| Historical Data | 2021 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Diagnosis, Treatment, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Pharmalucence Inc. (England), Koninklijke Philips N.V. (the Netherlands), GENERAL ELECTRIC (U.S.), Siemens AG (Germany), TOSHIBA CORPORATION (Japan), and others. |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | · Increasing prevalence of bone metastasis · Growing geriatric population · Increasing healthcare expenditures · Increasing R&D |
Bone Metastasis Market Highlights:
Frequently Asked Questions (FAQ) :
Bone metastasis is the condition when cancerous cells from other sites migrate to a bone.
Market is expected to exhibit a strong 9.4% CAGR over the forecast period till 2032.
Increasing prevalence of cancer is likely to be a major driver for the Bone Metastasis Market.
Americas hold the largest share in the Bone Metastasis Market.
Leading players in the Bone Metastasis Market include Merck, Bayer, and Pfizer, among others.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
